Development of an engineered probiotic for the treatment of branched chain amino acid related metabolic diseases

Ning Li (ningli@gmail.com)  
Synlogic Inc

Alex Tucker  
Ginkgo Bioworks

Jian-Rong Gao  
Synlogic

Lauren Renaud  
Synlogic Inc

Michael James  
Synlogic

Mary Castillo  
Synlogic Inc.

Silvia Galvan  
Ginkgo Bioworks

Rishi Jain  
Ginkgo Bioworks

Ryan Putman  
Ginkgo Bioworks

Scott Marr  
Ginkgo Bioworks

Dylan Carlin  
Ginkgo Bioworks

Kolea Zimmerman  
Ginkgo Bioworks

Laura Stone  
DSM Biotechnology Center, Delft, The Netherlands  https://orcid.org/0000-0001-9410-8220

Christopher Bergeron  
Synlogic

Mylene Perreault  
Synlogic Inc

Patrick Boyle
Development of an Engineered Microbe for the Treatment of Branched Chain Amino Acid Related Metabolic Diseases

Ning Li\textsuperscript{1*†}, Alex Tucker\textsuperscript{2†}, JR Gao\textsuperscript{1}, Lauren Renaud\textsuperscript{1}, Michael James\textsuperscript{1}, Mary Joan Castillo\textsuperscript{1}, Silvia Galvan\textsuperscript{2}, Rishi Jain\textsuperscript{2}, Ryan Putman\textsuperscript{2}, Scott Marr\textsuperscript{2}, Dylan Alexander Carlin\textsuperscript{2}, Kolea Zimmerman\textsuperscript{2}, Laura K. Stone\textsuperscript{2}, Chris Bergeron\textsuperscript{1}, Mylene Perreault\textsuperscript{1}, Patrick Boyle\textsuperscript{2}, Caroline Kurtz\textsuperscript{1*}

\textsuperscript{1}Synlogic Inc., Cambridge, Massachusetts, USA
\textsuperscript{2}Ginkgo Bioworks, Boston, USA
\*Equal contribution
\†Correspondence to Ning Li from ningli@gmail.com, Caroline Kurtz caroline@synlogictx.com
Abstract

Metabolic dysfunction arising from missing or impaired enzymes comprising the branched chain amino acid (BCAA) degradation pathway, especially those involving leucine, can result in the accumulation of toxic metabolic intermediates and cause severe metabolic disease. Removal of dietary BCAAs via their degradation by engineered microbes could be a viable approach to prevent BCAA-mediated disease sequelae. In this article, we describe the design and construction of an engineered leucine degrading strain of *E. coli* Nissle 1917, the improvement of the degradation pathway through high throughput screening, and the demonstration of strain activity in animal models monitored by disease and strain-specific biomarkers. This work provides a path for the development of engineered probiotic bacterial strains as a treatment for BCAA-related metabolic diseases and disorders in humans.
Introduction

Human proteins are comprised of 20 amino acids, 9 of which are deemed essential because they cannot be synthesized by the human body. Essential amino acids must therefore be obtained from the diet. The branched-chain amino acids (BCAAs) leucine (Leu), isoleucine, and valine belong to this group[1]. BCAAs are reported to promote protein synthesis, improve muscle mass production, stimulate post-exercise recovery, enhance immune function, and improve insulin secretion, most likely through the rapamycin (mTOR) signaling pathway (Figure 1A)[2-6]. BCAAs from dietary sources are largely absorbed via the gut intestinal tract, bypassing the liver, and delivered to the peripheral tissues[7-11]. The human pathways for BCAA catabolism involve many highly regulated enzymes, and impaired BCAA catabolism caused by genetic defects in pathway enzymes may result in metabolic diseases such as maple syrup urine disease (MSUD), propionic Acidemia (PA), methylmalonic acidemia (MMA), and isovaleryl acidemia (IVA), among others (Figure 1B)[7, 8, 12-14].

Frontline treatment for the aforementioned rare metabolic diseases includes dietary protein restriction[15-18]. Patients consume artificially formulated prescription protein food that has been depleted of one or more BCAAs. However, this treatment option is not without drawbacks. Education, poor availability of the proper food or inconvenience all result in poor compliance with the treatment diet, which is even more challenging in less-developed countries or regions. Therefore, treatments that maintain the ability to consume natural protein foods as part of daily dietary intake are a desired option to improve a patient’s quality of life[19-22].
Advances in synthetic biology techniques have enabled the engineering of microbes as potential therapies for a number of different diseases. For example, the probiotic strain *E. coli* Nissle 1917 (EcN) has been engineered to express multiple enzymes aimed at the metabolism of phenylalanine as a potential treatment for PKU[23]. Similarly, oral delivery of BCAA-degrading engineered microbes could be used as a therapeutic treatment option for BCAA-related metabolic diseases or disorders. Among the BCAAs, leucine is thought to play the most critical role in disease pathogenesis and therefore is targeted for dietary removal in patients with MSUD, IVA, 3-methylglutaconic aciduria type I and 3-hydroxy-3- methylglutaryl-CoA lyase deficiency[14]. In this article, we describe the genetic engineering of a leucine degradation pathway in the widely used probiotic strain, *E. coli* Nissle 1917. Following demonstration of its activity *in vitro*, we applied high throughput screening techniques to optimize the leucine degradation activity of the strain. We show that pathway optimization translates to increased *in vivo* leucine degradation activity in naïve mouse and non-human primate pharmacokinetic models as measured by tracking blood metabolites and a non-invasive, strain-specific urinary biomarker identified during the course of this study. In this work we present a process for the development of the engineered probiotic EcN with a multi-enzyme pathway and its optimization using high throughput screening for a broad therapeutic application targeting BCAA-related human diseases and disorders.
Results

**Leucine-degradation pathways engineered into E. coli Nissle 1917**

To engineer EcN for leucine degradation, we designed a three-enzyme pathway to catabolize leucine to isopentanol via ketoisocaproate and isopentanal intermediates. This pathway was composed of leucine dehydrogenase (LeuDH, from *Bacillus cereus*), ketoacid decarboxylase (KivD, from *Lactococcus lactis*), and alcohol dehydrogenase (Adh, from *Saccharomyces cerevisiae*) (Figure 2A). To enhance the transport of leucine into EcN, the gene encoding the *E. coli* BCAA transporter BrnQ was also included in the design[24]. The genes encoding the three catabolic pathway enzymes and the BrnQ transporter were assembled as a multi-cistronic operon in a low copy plasmid which was used to transform a genetically modified EcN strain (SYN469) with the following chromosomal changes: 1) genes encoding a second copy of the endogenous high affinity BCAA transporter LivKHMGF to facilitate additional import of leucine 2) deletion of the leucine biosynthetic gene *ilvC* to prevent BCAA production[25], and 3) deletion of the amino acid export gene, *leuE*, to prevent leucine export[26] (Figure 2B, SYN1980). The same plasmid was also used to transform wild type EcN resulting in strain SYN6034 (Figure 2C).

Following construction, leucine consumption by both strains was assessed *in vitro*. SYN1980 was able to consume leucine *in vitro* (Figure 2D), and the rates of leucine consumption between SYN1980 and SYN6034 were not significantly different, indicating that the accessory chromosomal modifications in the SYN1980 chassis did not affect the leucine consumption rate of the heterologous pathway (Figure 2D). However, the BrnQ transporter was required for optimal activity of the heterologous...
pathway, as elimination of the additional copy of BrnQ resulted in a >55% decrease in
the leucine consumption rate (Figure 2D, SYN1992 vs SYN1980). Since the accessory
modifications did not improve strain activity, focus was shifted to the three pathway
enzymes, LeuDH, KivD, or Adh, to explore the potential to improve the rate of leucine
degradation. Analysis of leucine pathway intermediates from SYN1980 demonstrated a
time-dependent accumulation of ketoisocaproate, suggesting that the KivD enzyme
could be a pathway bottleneck limiting maximal leucine degradation (Figure S1B,
SYN1980).

**Identification of leucine degrading enzymes with increased activity through high
throughput enzyme homolog screening and the generation of an improved
leucine consumption strain**

To improve the efficiency of leucine degradation, LeuDH, KivD and Adh were optimized
using a high throughput enzyme homolog screening and DNA assembly strategy. For
each enzyme, a library of ~1,200 homologs was designed to sample the full enzyme
sequence space in public sequence databases (Table 1). To enable the required
screening throughput, we developed spectrophotometric enzymatic assays for direct or
indirect measurement of LeuDH, KivD, and Adh activities in *E. coli* cell lysates (Figure
S2), which are amenable to automation for high throughput screening. A total of 1,175
candidate LeuDH enzymes were screened for the ability to deaminate leucine. The
initial round of screening identified 110 enzymes with activity on leucine. These 110
enzymes were further analyzed in a second screen, and 43 LeuDH enzymes had mean
activity higher than the *B. cereus* LeuDH expressed in the prototype strain SYN1980
(Figure 3A). The best-performing enzyme, LeuDH from *Cetobacterium ceti*, exhibited a 3.4x greater activity than the *B. cereus* LeuDH (Table S2).

Similarly, to identify a superior ketoisovalerate decarboxylase (KivD), a total of 1,296 candidate KivD enzymes were screened for decarboxylase activity on ketoisocaproate. Interestingly, the *L. lactis* KivD enzyme in the SYN1980 pathway did not have measurable activity when screened in the high throughput assay, so KivD activity is reported relative to the non-zero activity of the lysate-only negative control. The initial round of screening identified 55 enzymes with decarboxylase activity. The second round of screening demonstrated that >40 KivD enzymes had at least 6- to 8-fold increase in KivD activity relative to the background lysate activity (Figure 3B, Table S3).

For Adh enzyme screening, a library of 1,177 candidates was screened for the ability to reduce isopentanal to isopentanol. Similar to KivD in the decarboxylase assay, the *S. cerevisiae* ADH2 enzyme in the SYN1980 prototype strain did not exhibit activity in the Adh assay above the non-zero lysate-only background control. The *Equus caballus* Adh was found to have the desired activity on isopentanal during assay development and was used as a positive control for the Adh screens. We identified 55 Adh enzymes with Adh activity in our first round of screening. The second screening round identified 5 Adh enzymes with at least a 20-fold increase in Adh activity relative to the non-zero background lysate activity, and >10-fold higher than the positive control *E. caballus* Adh (Figure 3C, Table S4).

The top hits from each individual enzyme screening were assembled into a library of operons. These Leu catabolic operons were synthesized (*leuDH-kivD-adh*) and cloned into the same plasmid backbone conferring Leu catabolism in SYN1980, replacing the
original catabolic genes upstream of \textit{brnQ} (Figure 2B). Complete pathways encoded four-gene operons (\textit{leuDH-kivD-adh-brnQ}) in which the LeuDH, KivD, and Adh enzymes and their cognate ribosome binding sites (RBSs) were varied while the location and identity of the \textit{brnQ} RBS and coding sequence were held constant (Figure S3). Out of the 462 operons designed, 383 were successfully synthesized as plasmids and 354 were successfully transformed into the screening chassis SYN469 (SYN001, \textit{ΔilvC, ΔleuE, lacZ::Ptet-livKHMGF}). The successful library transformants were screened in a high throughput leucine consumption assay to identify operons conferring greater leucine consumption compared to SYN1980. For plate-to-plate standardization, each plate included control strains which harbored the prototype pathway (SYN1980) or variants lacking LeuDH (SYN1980 \textit{ΔleuDH}) or BrnQ (SYN1980 \textit{ΔbrnQ}). As shown in Figure 3D, strains were ranked based on leucine consumption, and 108 pathways demonstrated mean leucine consumption equivalent to or higher than the prototype pathway in SYN1980. Enzyme origin and RBS information are listed in Table 2.

The 3 strains with the highest leucine consumption rates (SYN5721, SYN5722 and SYN5729, all in SYN469 background) were further characterized. As observed in the pathway library screen, all 3 strains consumed leucine at a faster rate than the prototype strain SYN1980 (Figure S1A). Notably, the 3 strains with optimized pathways had drastically reduced levels of ketoisocaproate in the supernatant when compared to the control strains, indicating that a KivD bottleneck was relieved through the pathway optimization campaign (Figure S1B).

To understand the impact of leucine-specific host strain chromosomal modifications on the improved leucine-consuming pathways (the \textit{liv} operon, \textit{ilvC}, and \textit{leuE}), plasmids
from the top three strains were used to transform wild type EcN, resulting in strains SYN5941, SYN5942 and SYN5943, and the *in vitro* leucine consumption activity was evaluated for each strain (Figure 4). Similar to the prototype pathway (SYN1980 vs. SYN6034, Figure 4), the accessory gene modifications carried in SYN1980-derivative strains did not enhance activity over the wild type chassis strains. We reasoned that reduced host cell engineering would result in better strain fitness; therefore, we chose to move forward with characterization of a single optimized leucine catabolizing pathway in the wild type EcN background (SYN5941).

**Biomarker characterization and detection *in vivo***

To enable the assessment of strain activity *in vivo*, biomarkers of leucine consumption activity that could be identified in urine were developed. Glucuronidation reaction catalyzed by UDP-glucuronosyltransferase (UGT) is the major pathway for foreign chemical removal in humans as well as other animals[27, 28]. Therefore, we hypothesized that the end product of the leucine degradation pathway in SYN5941, isopentanol, may be converted by UGT into isopentyl glucuronide (IPG) and excreted in urine (Figure 5A)[27, 29, 30]. To test this hypothesis, isopentanol was orally administered to mice at 100, 250 or 500 mg/kg and urine was collected 4 hours later for detection of IPG. Isopentanol administration resulted in a dose-dependent recovery of IPG, with concentrations reaching 2.06 ± 0.33 µmol at the 500 mg/kg dose (Figure 5B). In naïve mice, a single dose of SYN5941 (5.62 x 10^{10} CFU) resulted in a significant increase in urinary IPG compared to treatment with vehicle or WT EcN (Figure 5C), demonstrating that the strain degraded leucine *in vivo*. 
To further investigate the potential of using IPG as a strain-specific biomarker for the evaluation of SYN5941 activity in humans, the baseline urinary IPG levels were analyzed from ten healthy human volunteers. All ten subjects were found to have very low background IPG levels (below the limit of detection ~ 0.16 µg/mL) (Figure S4). This suggests that IPG may be useful as a clinical biomarker, as the background signal for IPG would not be expected to confound the assessment of EcN leucine degradation activity in humans.

**Activity of engineered EcN in non-human primates**

We next examined the activity of leucine-consuming EcN strains in non-human primates (NHPs), as these animals have GI physiology and dietary patterns similar to humans. NHPs received a single dose of vehicle or bacteria concomitantly with 7 g of protein in the form of peptone. Leucine levels in plasma peaked approximately 1h post-peptone administration in vehicle-treated animals (Figure 6A). While SYN1980 did not lower the levels of leucine compared to vehicle treated animals, the optimized strain, SYN5941, displayed a statistically significant decrease in plasma leucine AUC\(_{0-6h}\) with a concomitant increase in urinary IPG (Figure 6B and C). Taken together, these results not only further validate strain activity *in vivo*, but also demonstrate that the strain optimization strategy translated to measurable improvements in leucine consumption *in vivo*.

**Discussion**

Human metabolic diseases and disorders caused by mutations in BCAA metabolic pathways are typically managed by diet, yet this can be a significant burden for patients, and in some cases, poor dietary management can prove to have life-threatening
consequences[20, 31]. Even when carefully followed, dietary restriction can cause significant pressure and create negative psychological issues for patients[19-21]. Several drugs are currently in development as treatments for diseases caused by mutations in BCAA metabolic pathways. For example, the small molecule, sodium phenylbutyrate, increases the activity of the branched-chain alpha-keto acid dehydrogenase enzyme complex and improves BCAA degradation[32]. Other groups have developed therapeutic mRNAs encoding missing or damaged pathway enzymes in PA or MMA patients[33, 34]. However, a challenge remains that each of these types of therapies can only target single pathway enzyme within already small patient populations (Figure 1). The high cost and small patient population results in minimal incentive for new drug development and continuously unmet needs for patients.

Synthetic biology brings huge potential to provide a clinical benefit to multiple disease indications with a single strain. Specifically, using engineered microbes to consume the BCAAs from the diet could be a promising alternative therapeutic approach for BCAA-related rare diseases since its strategy is simply to remove the BCAA from the food source itself and could apply to a wide range of patients regardless of the underlying genetic mutation.

In addition to inborn errors of metabolism, chronically elevated levels of BCAAs are associated with cardiometabolic diseases such as type 2 diabetes (T2D), obesity, and cardiovascular disease (Figure 1A)[5, 35-37]. Current evidence suggests that elevated BCAAs may not only be biomarkers for cardiometabolic diseases but may also play a role in the pathogenesis of these diseases. Further, reduced BCAA intake from daily food may serve to reduce the long-term risk of cardiometabolic diseases[38-40]. BCAA
consuming strains could provide a positive effect on overall metabolic fitness or even make intriguing prophylactic treatments for cardiometabolic diseases[41].

EcN was selected as the chassis to develop a strain capable of degrading BCAAs in this work. EcN’s safety, in its un-engineered form, has been validated by long-term use in humans, and some trials have been done safely in infants[42-44]. In its engineered form, EcN has demonstrated safety, tolerability, and target engagement in human clinical trials for the treatment of inborn errors of metabolism, such as phenylketonuria[23].

In this work, we demonstrated leucine consumption by the engineered and optimized probiotic EcN strain in preclinical animal models as proof of concept for the potential treatment of a broad range of disorders and diseases where leucine is a toxic metabolite. The LeuDH-KivD-Adh pathway was chosen because it does not require ATP for catalysis and this redox-neutral pathway can operate under anaerobic conditions mimicking the gastrointestinal environment. The proof-of-concept strain SYN1980 demonstrated that EcN could be engineered to consume leucine in vitro, with the leucine importer BrnQ being essential for optimal activity, yet this strain did not significantly lower leucine levels in vivo. To improve strain activity, a high throughput campaign targeting key enzymes was conducted and resulted in a ~ 3 x enhancement in the rates of leucine-consumption. Pathway improvements translated to improved leucine degradation rates in vivo, as the optimized strain exhibited significant leucine consumption in both mouse and NHP models.

Assessing the therapeutic activity of drugs in vivo is enabled by the ability to measure biomarker levels on samples collected using non-invasive procedures. Here we
identified a non-invasive method to measure isopentanol, the end product of leucine-
consuming strains, through identification of IPG, a glucuronic acid conjugate easily
measured in urine. The virtually non-existent background levels of IPG in human urine
make this a candidate biomarker for further development to provide a strain-specific
metabolite to monitor strain activity.

This work demonstrates the power of high throughput enzyme homolog screening to
identify enzymes and their combinations with increased activity by exploring natural
enzyme diversity and to balance metabolic pathways by exploring a large combinatorial
design space. Our results here also provide the first example of successful translation of
this in vitro improvement into in vivo biological activity and thus could be considered a
valid approach for engineered probiotic strain improvement for therapeutic development
in general.

Acknowledgements

Thanks to Dave Hava and Vincent Isabella for suggestions on drafting the manuscript
and Yves Millet for the initial design and construction.

Author Contributions

N.L. and C.K. conceived the project. P.B. and A.T. designed the screening studies. N.L.,
and J.G. designed and performed bacterial engineering and in vitro bacterial analysis.
L.R. and M.P. designed the in vivo studies and performed the data analysis with L.R.
performed the in vivo experiment. M.J. and M.J.C. developed mass spectrometry
method and detected in vivo biomarker. C.B. devised fermentation conditions and
provided essential materials. R.J., K.Z. and L.S. designed the high throughput enzyme
screening with R.J. and K.Z. conducted the assay. S.M. developed methods and
executed metabolites detection assays. S.G. constructed pathway strains. R.P. developed high throughput leucine consumption assay. R.P. and S.G. executed high throughput leucine consumption assay. A.C. sourced and designed enzyme libraries and designed pathway libraries. N.L. and A.T. supervised the project and wrote the manuscript with assistance from C.K..

**Data Availability**

All engineered strains described in this manuscript can be made available subject to a Material Transfer Agreement (MTA), which can be requested by contacting the corresponding authors. All requests will be reviewed by Synlogic and Ginkgo Bioworks to verify whether the request is subject to any intellectual property or confidentiality obligations. Additional data underlying the figures and supplementary information are available from the corresponding authors on reasonable request.

**Figure Legends**

**Figure 1. Branched chain amino acids and human diseases. A)** Branched chain amino acids (BCAAs) are essential amino acids which humans must obtain from protein food. They benefit human health but also are believed to relate to various diseases and disorders. **B)** Abnormal degradation of branched chain amino acids due to defective enzymes in human will result in severe disorders such as maple syrup urine disease (MSUD), propionic acidemia (PA), methylmalonic acidemia (MMA), isovaleryl acidemia (IVA), or 3-methylcrotonyl-CoA carboxylase deficiency (3-MCC).

**Figure 2. BCAA degradation pathway design, strain construction and in vitro activity. A)** Leucine consumption pathway designed to engineer into EcN in this study.
B) The scheme of prototype strain SYN1980. C) The scheme of prototype strain SYN6034. D) *In vitro* leucine consumption of engineered prototype strains (n = 2 for each timepoint and the error bar indicates the range of duplicates, solid lines indicate the linear regression fit of means for each strain).

**Figure 3. High throughput enzyme and operon screening results.** A) The top 110 LeuDH enzymes from the primary screen were re-screened to validate enzyme activity (n = 4). Activities are reported as fold-improvement over the *B. cereus* LeuDH activity (green dot and green dashed line). B) The top 55 KivD enzymes from the primary screen were re-screened for activity (n = 4). Activities are reported as fold-improvement over of L. lactis KivD, which was equivalent to the non-zero assay background (green dashed line). C) Top 55 Adh enzymes from the primary screen were re-screened for activity (n = 4). Since the strain expressing *S. cerevisiae* ADH2 had no measurable activity in this assay, activities are reported relative to *E. caballus* Adh (green dot, green dashed line). D) Pathway operons with optimized enzymes were screened for leucine consumption. Strains were assayed in biological replicates (n = 2 or 3, depending on the number of successful transformants). Data points are shown as dots, and the average for each strain is shown as a horizontal blue line. Control and reference strains are indicated with colored labels.

**Figure 4. Confirmation of leucine consumption activity of the top strains after scaling up in fermenter.** Original host strain was used as the chassis to test the activity (SYN1980, SYN5721, SYN5722, SYN5729, solid symbols with solid lines indicating the linear regression fit of means). The same four plasmids were also transformed into wild type EcN strain resulting in strains SYN6034, SYN5941,
SYN5942, SYN5943). The corresponding *in vitro* activity was measured (empty symbols with dotted line indicating the linear regression fit of means).

**Figure 5. In vivo biomarker validation and strain activity in mice.** A) Proposed pathway of *in vivo* isopentyl glucuronide (IPG) formation. B) IPG urinary recovery in response to oral administration of isopentanol in mice (n = 5 for each group). Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test (****p < 0.0001, ***p < 0.0007 versus vehicle). C) IPG urinary recovery in response to orally administered leucine consuming strain SYN5941 in mice (n = 5 for each group, bacterial dosed at 0 h, 1 h and 2 h and totaled at 5.62 e^{10} cells). All vehicle & SYN094 samples are below limit of quantification = 0.00003 µmol. Statistical analysis was performed using two-way ANOVA analysis followed by Tukey’s multiple comparison test (****p < 0.0001 versus vehicle).

**Figure 6. Efficacy of SYN1980 or SYN5941 in healthy nonhuman primates.** A) Effect of SYN1980 and SYN5941 on plasma leucine levels following oral administration of leucine consuming strains. Statistical analysis was performed using two-way ANOVA analysis followed by Tukey’s multiple comparison test (* p < 0.05 versus vehicle). B) Quantification of area under the curves (AUC) from plot A in this figure. Statistical analysis was performed using ordinary one-way ANOVA analysis (**p < 0.0051 versus vehicle) followed by Tukey’s multiple comparison test. C) Urinary IPG recovery following oral administration of leucine consuming strains. Statistical analysis was performed using one-way ANOVA analysis followed by Tukey’s multiple comparison test (**p < 0.005 versus vehicle).
Material and Methods

Strain construction

Refer below to Table S1 for a list of strains used in this publication. *Escherichia coli* Nissle 1917 (EcN), designated as SYN001 here, was purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ Braunschweig, *E. coli* DSM 6601).

The deletion of the *ilvC* and *leuE* gene was conducted by using P1 transduction from the corresponding BW25113 strains and the removal of antibiotic resistance cassettes via pCP20 and subsequent pCP20 removal. Insertion of P*tet-livKHPMF* cassette at *lacZ* locus was carried out by the lambda red recombineering method via pKD46 and subsequent pKD46 removal, followed by the removal of antibiotic resistance cassettes via pCP20 and subsequent pCP20 removal. For constructing plasmids, DNA fragments containing the BCAA-consuming operon under the control of various promoters were synthesized at GENEWIZ, IDT DNA, Ginkgo, or PCR-amplified from corresponding vectors from the Synlogic collection and cloned into a Synlogic vector containing an ampicillin resistance gene, a low copy number origin of replication (pSC101) and the regulatory control of the P*tet* promoter by Gibson assembly method. These plasmids were electroporated into SYN001 or other host strains. After electroporation (Eporator, Eppendorf, 1.8-kV pulse, 1-mm gap length electro-cuvettes), the transformed cells were selected as colonies on LB agar (Sigma, L2897) containing proper antibiotics.

Preparation of strains in flask

For analysis of leucine or other BCAA metabolism, cells were inoculated in 4 mL of 2xYT containing appropriate antibiotics in a 14-mL round bottom tube and incubated at
37 °C with shaking at 250 RPM overnight. The next day, cell cultures were diluted 1:100 in 50 mL of FM1 medium in 125-mL baffled flasks at 37 °C with shaking (250 RPM) for 2h, also with appropriate antibiotics. Cells were induced with the addition of anhydrous tetracycline (Sigma, ATC, 100 ng/mL final concentration) or IPTG (Sigma, 1 mM final concentration). All induction proceeded for 4h. Following induction, cells were centrifuged for 5 minutes at 8000 x g at 4 °C, washed once with an ice-cold formulation buffer (KH2PO4 (2.28 g/L) and K2HPO4 (14.5 g/L)) containing 15% of glycerol (pH 7.5). Finally, cells were concentrated 20-fold in the formulation buffer and stored at 80°C until the days of testing.

**Preparation of strains in fermenter**

A seed flask fermentation was started from a scraping of the frozen MCB culture in a cryovial with an inoculum loop into a 500-mL baffled flask with 50 mL FM1 media supplemented with 25 g/L glucose or FM2 media supplemented with 40 g/L glycerol and 100 µg/mL carbenicillin. This culture was grown overnight for ~15-16h at 37 °C and shaken at 350 RPM. Next day, a seed culture of ~30-40 OD₆₀₀ was used to inoculate a fermentation vessel with corresponding media and 100 µg/mL carbenicillin to a starting OD₆₀₀ of 0.15. The fermentation was grown at 37 °C and pH 7 with a dissolved oxygen setpoint of 60% for ~6h to achieve final biomass production. The fermentation growth phase was allowed to multiply for 2h until the OD₆₀₀ reached 1.5-3. At the target OD, the culture was induced by ATC at a final concentration of 600 ng/mL to activate the cells. The induction of cells continued for 4h until the generation of final biomass reached between 20-30 OD₆₀₀. Fermentation was harvested at 4h post-induction endpoint and
spun down by centrifuging culture broth for 30 min at ~ 5000 g at 4 °C. Cells were finally resuspended in glycerol/phosphate buffer, aliquoted and stored at -80°C.

**In vitro strain activity assays**

Frozen cells were thawed on ice and washed once with ice-cold MMG medium (M9 medium (Becton Dickinson) supplemented with 50 mM MOPS (3-(N-morpholino)propanesulfonic acid) and 0.5% glucose). Cell concentration was determined by measuring OD$_{600}$ with a spectrophotometer (1 OD$_{600}$ = 1e$^9$ cells/mL). Washed cells were diluted to 2e$^9$ cells/mL in MMG medium and 800 µL of the cell suspension was transferred into a well of a 96-deepwell plate, followed by addition and mixing of equal volume of assay media (MMG containing 20 mM leucine) using a multichannel pipet. The plate was covered by a breathe-EASIER membrane (Diversified Biotech, MA) and incubated statically at 37 °C in an anaerobic chamber. Bacterial broth samples were taken at specified time and centrifuged immediately for 10 minutes at 2270 x g and 4 °C. Supernatants were transferred into wells of a new plate and used for HPLC or LC-MS analysis.

**Enzyme library design and construction**

For each enzyme, a library of ~1,200 homologs was designed to sparsely sample all sequences in public sequence databases. Machine-learning–based bioinformatics tools were used to identify enzyme candidates for each of the three desired activities (leucine dehydrogenase, 1.4.1.9; ketoisovalerate decarboxylase, 4.1.1.1; and alcohol dehydrogenase 1.1.1.1) in public sequence databases (SwissProt and TrEMBL, together known as UniProt). DNA sequences encoding all library enzymes were optimized for expression in *E. coli*, synthesized in an inducible *E. coli* expression vector.
under the control of the T7 promoter and transformed into \textit{E. coli} for high throughput screening.

\textbf{Cultivation conditions for enzyme assays}

For each of the enzyme libraries screened, strains harboring library plasmids were transformed into \textit{E. coli} T7 expression host cells. 5 µL of thawed glycerol stocks were stamped into 500 µL/well of LB + 100 µg/mL carbenicillin (LB-Carb100) in half-height deepwell plates, which were sealed with AeraSeals. Samples were incubated at 37 °C and shaken at 1000 RPM in 80% humidity overnight. 50 µL/well of the resulting precultures were stamped into 450 µL/well of LB-Carb100 + 1 mM IPTG in half-height deepwell plates, which were sealed with AeraSeals. Samples were incubated at 30˚C and shaken at 1000 RPM in 80% humidity overnight. 250 µL/well of the resulting production cultures were stamped into deepwell plates containing 500 µL of phosphate buffered saline (PBS) and centrifuged for 10 minutes at 4000 x g. Supernatant was removed and the resulting cell pellet was resuspended in 200 µL of BugBuster Protein Extraction Reagent + 1 µL/mL purified benzonase + 1 µL/6 mL purified Lysozyme. Samples were incubated for 10 minutes at room temperature to generate the cell lysates used in \textit{in vitro} enzyme assays.

\textbf{LeuDH activity assay}

10 µL of lysate for the LeuDH library strains was transferred to a half-area flat-bottom plate containing 90 µL/well assay buffer (20 mM leucine, 200 mM Glycine, 200 mM KCl, 0.4 mM NAD, pH 10.5). Optical measurements were taken on a plate reader, with absorbance readings taken at 340 nm for 10 minutes. The resulting kinetic data was used to resolve the maximum rate of NAD+ reduction, a proxy for LeuDH activity.
**KivD activity assay**

10 µL of lysate for the KivD library strains was transferred to a half-area flat-bottom plate containing 90 µL/well assay buffer (100 mM PIPES-KOH, 100 mM potassium glutamate, 1 mM dithiothreitol, 0.4 mM NAD, 1.5 mM thiamine pyrophosphate, 10 mM magnesium glutamate, 20 mM ketoisocaproate (KIC), 1 U/mL *S. cerevisiae* aldehyde dehydrogenase pH 7.5). The coupling enzyme (*S. cerevisiae* aldehyde dehydrogenase) was used to indirectly measure KivD activity on KIC. Optical absorbance measurements were taken over 10 minutes. The resulting kinetic data was used to determine KivD activity.

**Adh activity assay**

10 µL of lysate for the Adh library strains was transferred to a half-area flat-bottom plate containing 90 µL/well assay buffer (50 mM MOPS buffer, 0.4 mM NADH, and 30 mM isovaleraldehyde, pH 7.0). Optical absorbance measurements were taken on a plate reader at 340 nm for 10 minutes. The resulting kinetic data was used to resolve the maximum rate of NADH oxidation, a proxy for ADH activity.

**Pathway enzyme selection and operon library assembly**

Selected top enzymes were incorporated in the final operon designs with various RBS strength to balance flux of the leucine-consuming pathway. Among the 3 RBSs, two were designed using the RBS Calculator to have translation initiation rates of approximately 5,000 au and approximately 50,000 au[45-48]. In addition to designing two conventional RBSs for each enzyme, we also included an RBS that was co-translationally coupled to a short leader peptide, in what is termed a bicistronic design[49]. RBS-enzyme pairs were assembled into a partial combinatorial library of
462 pathways. Each pathway contains either conventional RBSs or BCD-type RBSs, but not both. The gene order was held constant (leuDH-kivD-adh).

These leucine catabolic pathways were synthesized (leuDH-kivD-adh) and cloned into the same plasmid backbone conferring leucine catabolism in SYN1980, replacing the original catabolic genes upstream of brnQ. Complete pathways encoded four-gene operons (leuDH-kivD-adh-brnQ) in which the LeuDH, KivD, and Adh enzymes and their cognate RBSs are varied while the location and identity of the brnQ RBS and coding sequence are held constant. Out of the 462 operons designed, 383 were successfully synthesized as plasmids and 354 were successfully transformed into the screening chassis SYN469 (SYN001, ΔilvC, ΔleuE, lacZ::Ptet-livKHMGF).

**Operon screening**

The successful library transformants were screened in a high throughput leucine consumption assay to identify operons conferring greater leucine consumption compared to SYN1980. All pathway-containing strains were cultured and screened for leucine consumption in 96-well plates. For plate-to-plate standardization, each plate included control strains which harbored the prototype pathway (SYN1980) or variants lacking LeuDH (SYN1980 ΔleuDH) or BrnQ (SYN1980 ΔbrnQ).

**Ethical statement**

All procedures performed on animals were in accordance with the humane guidelines for ethical and sensitive care by the Institutional Animal Care and Use Committee (IACUC) of the U.S. National Institutes of Health. Procedures and protocols related to mouse studies were reviewed and approved by Mispro Biotech Services’ Institutional Animal Care and Use Committee. Standard operating procedures related to NHP
studies have been reviewed and approved by Charles River Laboratories’ Institutional Animal Care and Use Committee.

**Biomarker study in mice**

A total of 72 female C57BL/6J mice aged 19 weeks, from Jackson Laboratories, were acclimated for a minimum of 4 days. The vehicle control used for this study was filtered water, and the Isopentanol chemical compound was pharmaceutical grade 3-methyl-1-butanol (Sigma Aldrich). Mice were tail marked with a Sharpie marker, weighed, and randomized by body weight into 4 groups each containing 18 mice. Group 1 animals were given a 200 µL oral gavage dose of water, Group 2 animals were given a 200 µL oral gavage dose of 100 mg/kg isopentanol, Group 3 animals were given a 200 µL oral gavage dose of 250 mg/kg isopentanol, and Group 4 animals were given a 200 µL oral gavage dose of 500 mg/kg isopentanol. Once dosing was completed the animals were placed 3 per cage into metabolic cages (Tecniplast 3600M021) with *ad libitum* access to food and water. After a period of 4 hours the animals were individually removed from the metabolic cages and urine was collected by free-catch into an Eppendorf tube. The free-catch urine was then combined with the urine collected from the metabolic cage and samples were plated for analysis.

**Non-human primate (NHP) study**

A total of twelve male cynomolgus non-human primates (NHP), approximately 2-5 years of age, were housed at the Charles River Laboratories (CRL) where studies were conducted by experienced staff members. Samples were collected at CRL and shipped to Synlogic where they were plated for analysis. Due to the limited number of animals available per study, three separate studies were conducted, and the results were
combined for analysis. In each study NHP’s were separated into two groups. Each group was orally dosed into the stomach with three compounds; 14 mL of peptone (500 g/L), followed by 7.8 mL of vehicle (PBS + 15% glycerol) or bacteria (SYN1980 or SYN5941), followed by 5 mL of 0.36 M bicarbonate, and then finally a small amount of water to rinse the material from the gavage tube. The animals were then placed individually into cages with clean urine collection pans. After a period of 6 hours the urine pans were removed, and the urine was collected into 50-mL tubes and weighed. Study 1 (NHP20192881) had 12 NHP’s separated into 6 animals for group 1 receiving SYN1980 bacteria, and 6 animals for group 2 receiving SYN5941 bacteria. Study 2 (NHP20192884) had 11 NHP’s separated into 5 animals for group 1 receiving Vehicle, and 6 animals for group 2 receiving SYN5941 bacteria. Study 3 (NHP20197305) had 11 NHP’s separated into 5 animals for group 1 receiving Vehicle, and 6 animals for group 2 receiving SYN1980 bacteria.

**Statistical analysis**

Raw data generated was entered in a Microsoft Excel (Microsoft, Seattle, WA) spreadsheet and transferred to GraphPad Prism 8.0 (GraphPad Software, San Diego, CA). Statistical analysis was performed using GraphPad Prism and the statistical analysis was performed using two-way ANOVA followed by Tukey’s multiple comparison test. Significance was set as p < 0.05.

**HPLC analysis**

A Shimadzu Prominence-i LC-2030C HPLC system was used. For leucine analysis, the analytical column was Luna 5 mm C18(2) LC column (50 x 2 mm) (Phenomenex) fitted with a guard column (4 x 2 mm) of the same type. The mobile phase was composed
potassium phosphate buffer (0.02 M; pH 6.9) (A) and acetonitrile–methanol-water (45:40:15, v/v/v) (B) under isocratic elution condition: 70% A and 30% B for 5 min at a flow rate 0.5 mL/min. For analysis of leucine, the analytical column was Luna 5 m C18(2) LC column (100 x 2 mm) (Phenomenex) fitted with the same guard column and isocratic elution condition was the same except for running for 10 minutes. The supernatants were derivatized with OPA reagent (Agilent) according to the manufacturer’s instruction and 3 μL of derivatized samples was injected into the column. The absorbance detector was set at 338 nm and the temperature of the column was maintained at 40 °C. Leucine quantitated in bacterial supernatant, plasma, and urine by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) using either an Ultimate 3000 UHPLC-TSQ Quantum or a Vanquish UHPLC-TSQ Altis system. Samples were extracted with 9 parts 2:1 acetonitrile:water containing 1 µg/mL leucine-d3 as an internal standard, vortexed, and centrifuged. Supernatants were diluted with 9 parts 0.1% formic acid and analyzed concurrently with standards processed as above from 0.8 to 1000 µg/mL. Samples were separated on a Phenominex Synergi 4 μm Hydro-RP 80A, 75 x 2 mm using a 0.1% formic acid (A), 0.1% formic acid/acetonitrile (B) at 0.3 mL/min and 50 °C. After a 2 μL injection and an initial 5% B hold from 0 to 0.5 minutes, analytes were gradient eluted from 5 to 90% B over 0.5 to 1.5 minutes followed by high organic wash and aqueous equilibration steps. Analytes were detected using Selected Reaction Monitoring (SRM) of compound specific collision induced fragments in electrospray positive ion mode (leucine: 132>86). SRM chromatograms were integrated and the unknown/internal standard peak area ratios were used to calculate concentrations against the standard curve.
**GC-MS quantitation of isopentanol**

Quantitation of isopentanol in bacterial supernatant and urine samples was performed using Agilent gas chromatography-mass spectrometry (GC-MS) with Restek Stabilwax-MS 30 m x 0.25 mm x 0.25 µm column. Briefly, 500 µL of extraction solution was added to 100 µL of samples. Extraction solution was prepared by spiking 10 µL Isopentanol-d11 (10 mg/mL) in 5 mL ethyl acetate for a final concentration of 20 µg/mL isopentanol-d11. The samples were then mixed vigorously and centrifuged at 16,000 x g for 15 mins at room temperature. The following are the GC-MS parameters used for the analysis: 1 µL injection volume; gas (He) flow rate of 1 mL/min; 40 °C for 5 minutes, ramped to 220 °C for 3.6 minutes, and held at 220 °C for 5 minutes. Selected ion monitoring (SIM) was used for quantitative MS analysis. The following target ions were monitored for quantitation: isopentanol (55.1) and internal standard isopentanol-d11 (62.2).

**LC-MS/MS quantitation of isopentyl glucuronide**

Isopentyl glucuronide was quantified using a liquid chromatography triple quadrupole tandem mass spectrometry (LC-MS/MS) Thermo TSQ Altis system. In a conical bottom plate, 10 µL of standards and samples were diluted with 90 µL water containing 5 µg/mL of internal standard (Isopentyl-glucuronide-d11).

Chromatographic gradient separation was carried out using an Accucore aQ C18 column 2.6 µm 100 Å, 100 x 2.1 mm column at 40 °C with mobile phases 10 mM ammonium acetate in water (A) and 10 mM ammonium acetate in acetonitrile (B). Multiple reaction monitoring in negative mode was used for tandem MS analysis. The following mass transitions were monitored for quantitation: isopentyl glucuronide (263.1/75) and internal standard isopentyl glucuronide-d11 (274.1/75).
**LC-MS/MS method for leucine quantification**

Leucine was quantified in bacterial supernatant by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) using either an Ultimate 3000 UHPLC-TSQ Quantum or a Vanquish UHPLC-TSQ Altis system. Samples were extracted with 9 parts of acetonitrile : water = 2 :1 containing 1 µg/mL leucine-d3 as an internal standard, vortexed, and centrifuged. Supernatants were diluted with 9 parts 0.1% formic acid and analyzed concurrently with standards processed as above from 0.8 to 1000 µg/mL. Samples were separated on a Phenomenex Synergi 4 µm Hydro-RP 80A, 75 x 2 mm using a 0.1% formic acid (A), 0.1% formic acid/acetonitrile (B) at 0.3 mL/min and 50°C. After a 2 µL injection and an initial 5% B hold from 0 to 0.5 minutes, analytes were gradient eluted from 5 to 90% B over 0.5 to 1.5 minutes followed by high organic wash and aqueous equilibration steps. Analytes were detected using Selected Reaction Monitoring (SRM) of compound specific collision induced fragments in electrospray positive ion mode (leucine: 132>86, isoleucine: leucine-d3: 135>89). SRM chromatograms were integrated, and the unknown/internal standard peak area ratios were used to calculate concentrations against the standard curve.

**LC-MS methods for pathway intermediates**

Leucine (Leu), ketoisocaproate (KIC), and isovaleraldehyde (IVA) were detected by LCMS analysis performed on a Thermo Ultimate 3000 UPLC system with a Thermo Q-Exactive quadrupole-orbitrap mass detector and a Thermo Accucore PFP column (2.1 x 100 mm, 2.6 µm packing) using the following elution solvents: A=0.1% formic acid and 0.1% TFA in water; B=0.1% formic acid in acetonitrile. The gradient was at 0.5 mL/min of 1% B in A for 60 seconds, followed by a linear ramp from 1% to 40% B over 270
seconds. The column is then flushed with 95% B in A for 60 seconds, and re-
equilibrated with 1% B in A for 180 seconds. MS acquisition was from 0.8 to 5.3
minutes. Column effluent is introduced into the mass spectrometer via a standard
Thermo ESI source with positive mode ionization at +3800V, vaporizer temperature of
400 °C, and ion transfer tube temperature of 375 °C. Thermo reports gas flow rates in
arbitrary units probably approximating L/min at STP. Set points were: sheath gas, 60;
aux gas, 30; sweep gas, 1. To increase data acquisition rate, orbitrap resolution was set
to 17,500. Quadrupole resolution was 1 m/z. 2-(Dimethylamino)ethylhydrazine was
used to derivatize both aldehydes and keto acids for analysis in positive mode. A buffer
of 0.5 M acetic acid and 0.5 M sodium acetate in methanol was used for the
quantification of leucine acid and leucine aldehyde, while also measuring non-
derivatized leucine.

References

1. Holeček, M., Branched-chain amino acids in health and disease: metabolism, alterations in blood
   plasma, and as supplements. Nutrition & Metabolism, 2018. 15(1): p. 33.
2. Neishabouri, S.H., S.M. Hutson, and J. Davoodi, Chronic activation of mTOR complex 1 by
   branched chain amino acids and organ hypertrophy. Amino Acids, 2015. 47(6): p. 1167-1182.
3. Nair, K.S. and K.R. Short, Hormonal and Signaling Role of Branched-Chain Amino Acids. The
   Journal of Nutrition, 2005. 135(6): p. 1547S-1552S.
4. Jewell, J.L., R.C. Russell, and K.-L. Guan, Amino acid signalling upstream of mTOR. Nature
   Reviews Molecular Cell Biology, 2013. 14(3): p. 133-139.
5. Lynch, C.J. and S.H. Adams, Branched-chain amino acids in metabolic signalling and insulin
   resistance. Nature Reviews Endocrinology, 2014. 10(12): p. 723-736.
6. Gingras, A.C., B. Raught, and N. Sonenberg, Regulation of translation initiation by FRAP/mTOR.
   Genes Dev, 2001. 15(7): p. 807-26.
7. Brosnan, J.T. and M.E. Brosnan, Branched-chain amino acids: enzyme and substrate regulation. J
   Nutr, 2006. 136(1 Suppl): p. 207S-115.
8. Harper, A.E., R.H. Miller, and K.P. Block, Branched-chain amino acid metabolism. Annu Rev Nutr,
   1984. 4: p. 409-54.
9. Hutson, S.M., Regulation of substrate availability for the branched-chain alpha-keto acid
dehydrogenase enzyme complex. Ann N Y Acad Sci, 1989. 573: p. 230-9.
10. Hutson, S.M. and T.R. Hall, Identification of the mitochondrial branched chain aminotransferase
    as a branched chain alpha-keto acid transport protein. J Biol Chem, 1993. 268(5): p. 3084-91.
11. Adeva-Andany, M.M., et al., *Enzymes involved in branched-chain amino acid metabolism in humans*. Amino Acids, 2017. 49(6): p. 1005-1028.

12. Fraser, J.L. and C.P. Venditti, *Methylmalonic and propionic acidemias: clinical management update*. Curr Opin Pediatr, 2016. 28(6): p. 682-693.

13. Tanaka, K., et al., *Isovaleric acidemia: a new genetic defect of leucine metabolism*. Proc Natl Acad Sci U S A, 1966. 56(1): p. 236-42.

14. Manoli, I. and C.P. Venditti, *Disorders of branched chain amino acid metabolism*. Transl Sci Rare Dis, 2016. 1(2): p. 91-110.

15. Hauser, N.S., et al., *Variable dietary management of methylmalonic acidemia: metabolic and energetic correlations*. Am J Clin Nutr, 2011. 93(1): p. 47-56.

16. Frazier, D.M., et al., *Nutrition management guideline for maple syrup urine disease: an evidence-and consensus-based approach*. Mol Genet Metab, 2014. 112(3): p. 210-7.

17. Lea, D., et al., *Dietary Management of Propionic Acidemia: Parent Caregiver Perspectives and Practices*. J Parenter Enteral Nutr, 2019. 43(3): p. 434-437.

18. Pinto, A., et al., *Dietary practices in isovaleric acidemia: A European survey*. Mol Genet Metab Rep, 2017. 12: p. 16-22.

19. Packman, W., et al., *Psychosocial issues in families affected by maple syrup urine disease*. J Genet Couns, 2007. 16(6): p. 799-809.

20. De Castro-Hamoy, L.G., et al., *Challenges in the management of patients with maple syrup urine disease diagnosed by newborn screening in a developing country*. J Community Genet, 2017. 8(1): p. 9-15.

21. Packman, W., et al., *Young adults with MSUD and their transition to adulthood: psychosocial issues*. J Genet Couns, 2012. 21(5): p. 692-703.

22. Simon, E., M. Schwarz, and U. Wendel, *Social outcome in adults with maple syrup urine disease (MSUD)*. J Inherit Metab Dis, 2007. 30(2): p. 264.

23. Isabella, V.M., et al., *Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria*. Nat Biotechnol, 2018. 36(9): p. 857-864.

24. Zhu, J., et al., *Enhancement of precursor amino acid supplies for improving bacitracin production by activation of branched chain amino acid transporter BrnQ and deletion of its regulator gene lrp in Bacillus licheniformis*. Synth Syst Biotechnol, 2018. 3(4): p. 236-243.

25. Li, K.H., et al., *Biological Functions of ilvC in Branched-Chain Fatty Acid Synthesis and Diffusible Signal Factor Family Production in Xanthomonas campestris*. Front Microbiol, 2017. 8: p. 2486.

26. Kutukova, E.A., et al., *The yeaS (leuE) gene of Escherichia coli encodes an exporter of leucine, and the Lrp protein regulates its expression*. FEBS Lett, 2005. 579(21): p. 4629-34.

27. King, C.D., et al., *UDP-glucuronosyltransferases*. Curr Drug Metab, 2000. 1(2): p. 143-61.

28. Ritter, J.K., *Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions*. Chem Biol Interact, 2000. 129(1-2): p. 171-93.

29. Kamil, I.A., J.N. Smith, and R.T. Williams, *The metabolism of aliphatic alcohols; glucuronide formation*. Biochem J, 1951. 49(3): p. xxxviii.

30. Webley, D.M. and P.C. De Kock, *The metabolism of some saturated aliphatic hydrocarbons, alcohols and fatty acids by Proactinomyces opacus Jensen (Nocardia opaca Waksman & Hendrik)*. Biochem J, 1952. 51(3): p. 371-5.

31. Macdonald, A., et al., *Adherence issues in inherited metabolic disorders treated by low natural protein diets*. Ann Nutr Metab, 2012. 61(4): p. 289-95.

32. Zubarioglu, T., et al., *Impact of sodium phenylbutyrate treatment in acute management of maple syrup urine disease attacks: a single-center experience*. J Pediatr Endocrinol Metab, 2020.

33. An, D., et al., *Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia*. Cell Rep, 2017. 21(12): p. 3548-3558.
34. Jiang, L., et al., Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat Commun, 2020. 11(1): p. 5339.
35. Wang, T.J., et al., Metabolite profiles and the risk of developing diabetes. Nat Med, 2011. 17(4): p. 448-53.
36. Asghari, G., et al., High dietary intake of branched-chain amino acids is associated with an increased risk of insulin resistance in adults. J Diabetes, 2018. 10(5): p. 357-364.
37. Zheng, Y., et al., Cumulative consumption of branched-chain amino acids and incidence of type 2 diabetes. Int J Epidemiol, 2016. 45(5): p. 1482-1492.
38. Fontana, L., et al., Decreased Consumption of Branched-Chain Amino Acids Improves Metabolic Health. Cell Rep, 2016. 16(2): p. 520-530.
39. Cummings, N.E., et al., Restoration of metabolic health by decreased consumption of branched-chain amino acids. J Physiol, 2018. 596(4): p. 623-645.
40. Karusheva, Y., et al., Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: a randomized controlled crossover trial. Am J Clin Nutr, 2019. 110(5): p. 1098-1107.
41. White, P.J. and C.B. Newgard, Branched-chain amino acids in disease. Science, 2019. 363(6427): p. 582-583.
42. Behnsen, J., et al., Probiotics: properties, examples, and specific applications. Cold Spring Harb Perspect Med, 2013. 3(3): p. a010074.
43. Lodinova-Zadnikova, R. and U. Sonnenborn, Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate, 1997. 71(4): p. 224-32.
44. Henker, J., et al., Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J, 2008. 27(6): p. 494-9.
45. Salis, H.M., E.A. Mirsky, and C.A. Voigt, Automated design of synthetic ribosome binding sites to control protein expression. Nat Biotechnol, 2009. 27(10): p. 946-50.
46. Espah Borujeni, A., A.S. Channarasappa, and H.M. Salis, Translation rate is controlled by coupled trade-offs between site accessibility, selective RNA unfolding and sliding at upstream standby sites. Nucleic Acids Res, 2014. 42(4): p. 2646-59.
47. Espah Borujeni, A. and H.M. Salis, Translation Initiation is Controlled by RNA Folding Kinetics via a Ribosome Drafting Mechanism. J Am Chem Soc, 2016. 138(22): p. 7016-23.
48. Espah Borujeni, A., et al., Precise quantification of translation inhibition by mRNA structures that overlap with the ribosomal footprint in N-terminal coding sequences. Nucleic Acids Res, 2017. 45(9): p. 5437-5448.
49. Mutalik, V.K., et al., Precise and reliable gene expression via standard transcription and translation initiation elements. Nat Methods, 2013. 10(4): p. 354-60.
FIGURES

Figure 1.

A

B
Figure 2.

A

leucine (Leu)

leucine dehydrogenase (LeuDH)

ketoisocaproate (KIC)

ketoacid decarboxylase (KivD)

isovaleraldehyde (IVAL)

alcohol dehydrogenase (Adh)

isopenanol (IVOL)

B

Leucine

LeuDH

KIC

IVAL

IVOL

LeuKHMGP

SmQ

LEU

aTc

ΔivC

ΔleuE
Figure 3.

A

Relative LeuDH activity

LeuDH

B

Relative KivD activity

KivD

C

Relative Adh activity

Adh

D

Leucine consumption (mM)

Strain

Figure 4.

Leucine (mM)

Time (h)

SYN469

SYN001

SYN1980

SYN6034

SYN5721

SYN5941

SYN5722

SYN5942

SYN5729

SYN5943
Figure 5.

A

\[ \text{Isopentanol} + \text{UDP-D-glucuronate} \rightarrow \text{Isopentyl glucuronide} \]

B

![Graph showing IPG (µmol) levels for Vehicle, 100mpk, 250mpk, and 500mpk](image)

C

![Graph showing IPG (µmol) AUC](image)

Figure 6.

A

![Graph showing leucine levels over time](image)

B

![Graph showing AUC (mM * hour)](image)
TABLES

Table 1. Enzyme library composition

| Library | Bacteria | Fungi | Animal | Plant | Total Designs |
|---------|----------|-------|--------|-------|---------------|
| LeuDH   | 1129     | 11    | 23     | 12    | 1175          |
| KivD    | 783      | 508   | 1      | 4     | 1296          |
| Adh     | 654      | 273   | 128    | 122   | 1177          |

Table 2. Operon composition and leucine degradation rates of selected pathways

| Strain   | Rate relative to SYN1980 | RBS       | LeuDH source | RBS       | KivD source | RBS       | Adh source |
|----------|--------------------------|-----------|--------------|-----------|-------------|-----------|------------|
| SYN5721  | 3.8                      | BCD       | C. ceti LeuDH| BCD       | E. inicta KivD | BCD       | A. dieselolei Adh |
| SYN5722  | 3.7                      | RBS TIR=50,000 au | C. ceti LeuDH| RBS TIR=50,000 au | E. inicta KivD | RBS TIR=5,000 au | R. bacterium NRL2 Adh |
| SYN5729  | 2.5                      | BCD       | C. ceti LeuDH| BCD       | E. inicta KivD | BCD       | R. bacterium NRL2 Adh |
Supporting Information

Figures

Figure S1. Intermediate analysis of leucine consuming strains. To better understand the difference between prototype strain SYN1980 and the improved strains SYN5721, SYN5722 and SYN5729, standard in vitro assay was performed where substrate leucine A), key intermediates ketoisocaproate B) and isovaleraldehyde C) were analyzed using LCMS respectively (n = 3 for each timepoint and error bar indicates standard deviation, expect for SYN1980 where n = 1 for each timepoint).
**Figure S2. Enzyme activities measured in high throughput.** A) LeuDH activity on leucine was measured by the reduction of NAD$^+$ to NADH. B) An enzyme-coupled reaction was used to measure KivD activity on α-ketoisocaproate. KivD activity was indirectly measured as rate of NAD$^+$-dependent oxidation of isopentanal by aldehyde dehydrogenase. C) Adh activity was measured by the NADH-dependent reduction of isopentanal.

**Figure S3. Combinatorial pathway design with optimized pathway enzymes.** To construct the optimized pathways, each selected pathway enzyme (6 LeuDH enzymes, 3 KivD enzymes, and 3 Adh enzymes) were each paired with 3 RBSs. The RBS-enzyme pairs were combined in a partial combinatorial library, maintaining the gene order of the prototype pathway, and keeping the plasmid-encoded BrnQ intact.
Figure S4. IPG background level in human volunteers. Urinary Isopentyl glucuronide concentration was determined from non-fasted healthy subjects. All levels were mostly zero. The limit of quantitation (LOQ) for the assay was 0.16 μg/mL.
### Table S1. List of strains used in this work

| Strain   | Genotype | Description                                                                 |
|----------|----------|----------------------------------------------------------------------------|
| SYN001   | *E. coli* Nissle 1917 | Wild type bacterium                                                        |
| SYN094   | SYN001, with strep resistance | Wild type bacterium selected for streptomycin resistance                   |
| SYN469   | SYN001, Δ*ilvC*, Δ*leuE*, lactZ::P<sub>tet</sub>-*livKHMGF* | Bacterium with *ilvC* and *leuE* knockouts and chromosomal integration of inducible *livKHMPGF* operon |
| SYN1980  | SYN469, pSC101-*tet-leuDH-kivD-adh-brnQ-ampR* | Bacterium with plasmid containing *leuDH-kivD-adh-brnQ* operon, *ilvC* and *leuE* knockouts and chromosomal integration of inducible *livKHMPGF* operon |
| SYN1992  | SYN469, pSC101-*tet-leuDH-kivD-adh-ampR* | Bacterium with plasmid containing *leuDH-kivD-adh* operon, *ilvC* and *leuE* knockouts and chromosomal integration of inducible *livKHMPGF* operon |
| SYN5721  | SYN469, pSC101-*tet-leuDH-kivD-adh-brnQ-ampR* opt 1 | Bacterium with plasmid containing *leuDH-kivD-adh-brnQ* operon, *ilvC* and *leuE* knockouts and chromosomal integration of inducible *livKHMPGF* operon |
| SYN5722  | SYN469, pSC101-*tet-leuDH-kivD-adh-brnQ-ampR* opt 2 | Bacterium with plasmid containing *leuDH-kivD-adh-brnQ* operon, *ilvC* and *leuE* knockouts and chromosomal integration of inducible *livKHMPGF* operon |
| SYN5729  | SYN469, pSC101-*tet-leuDH-kivD-adh-brnQ-ampR* opt 3 | Bacterium with plasmid containing *leuDH-kivD-adh-brnQ* operon, *ilvC* and *leuE* knockouts and chromosomal integration of inducible *livKHMPGF* operon |
| SYN5941  | SYN001, pSC101-*tet-leuDH-kivD-adh-brnQ-ampR* opt 1 | Bacterium with plasmid containing *leuDH-kivD-adh-brnQ* operon, |
| SYN5942  | SYN001, pSC101-*tet-leuDH-kivD-adh-brnQ-ampR* opt 2 | Bacterium with plasmid containing *leuDH-kivD-adh-brnQ* operon, |
| SYN5943  | SYN001, pSC101-*tet-leuDH-kivD-adh-brnQ-ampR* opt 3 | Bacterium with plasmid containing *leuDH-kivD-adh-brnQ* operon, |
| SYN6034  | SYN001, pSC101-*tet-leuDH-kivD-adh-brnQ-ampR* | Bacterium with plasmid containing *leuDH-kivD-adh-brnQ* operon |
Table S2. LeuDH enzyme performance

| LeuDH Source                  | Activity relative to *B. cereus* LeuDH | Protein sequence                                                                 |
|-------------------------------|----------------------------------------|---------------------------------------------------------------------------------|
| *Bacillus cereus* (prototype) | 1.0                                    | MTLEIFELEYEQVVFCC0KEGKLAYHIDTLGPAGTKGGTRMWTYD3EAEDRALAKGMYTKNAAALNLGQGAGTVGDDPKNDEKALSEMFIRALGARYQGLNQG5YTAEDQVTTVDSDMOHETFDPYTIQGSS  |
|                               |                                        | GSSPGNSPVSPTYVAGYVRGKMAAAKEAFGTNLEGKIVAGQGYNVAYHLCWCAHAEAKLVTDVNEAK VQRAVEEGASAEPEVNNEGSCYECIDYXPCALGAT再次TIPOLKAKVAGSANNOLEDGRDIIHSMGYV YAP0YVINAAGVGNVNAWDEYGNYRERALKREVSEYDTAVKIEISKRGUIAYAAGRLAEERIAGLKNRS TYLHGRIHIIYR. |
| *Cetobacterium ceti*          | 3.4                                    | MN9FMKMFNEYNEQLVFMDFSETLKDICTCHOHTMGPGTAGLGRPVNIVYSEDEAVDEVRG4RMTGYYAA CAGLNLGGNGKTTLGDAKHSKESSEYFRLGKVQLSQGNLYTAE5DNVTAMNTOYMETQDVVLNGSGN LPSMTVAGYFAGM4LAMKdleFFDSSEIRFAGQVQGQHYLVLLGKNFKEAKYKTEINE SYIERNMKHEPKHEFIFDSPOHYSLEDVFVPCALGSKNKTDIFECFPIAGDTANVNLEREANTMKKIR ILYAP0YVAGAGGLILGNNVYHLGNYKNALEVLELFYNNADSLNISTHAANAFIKQIKGGQLN NFKIR |
| *Hymenobacter daecheongensis* | 2.2                                    | MVEKGALT07FSFQGAEGHLEQVFCHDHE4TGLRAI6HINTVLGPGTAGTMWYASAEDALNMTLRLG SRKMTYKAASGLNLGQAKVIGADAKTKTEALLRLKRFGRFQLNLYTAE5DNMTDREYRMIEMTK HVA5LPGMSGGSSPSTVAGTYMGKAAKAAGFSGSLARKRAGQVQGQHYLVLLGKNFKEAKYKTEINE YLVDYEDRAEALANTLFAGMKVQGQYLDQYVDYDFCNPACALGATINDIT4GRLKQVAGCANNQGONN VHPGALGVERSIVYAPDFUN4AGGLILGNNVYHLGNYKNALEVLELFYNNADSLNISTHAANAFIKQIKGGQLN NFKIR |
| *Hymenobacter sp. CRA2*       | 1.9                                    | MVEIGALPETSIFQGADHGQEUVFCHDHERGLRAI6HINTVLGPGTAGTMWYATAEAALNMTLRLG SRKMTYKAASGLNLGQAKVIGADAKTKTEALLRLKRFGRFQLNLYTAE5DNMTDREYRMIEMTK HVA5LPGMSGGSSPSTVAGTYMGKAAKAAGFSGSLARKRAGQVQGQHYLVLLGKNFKEAKYKTEINE YLVDYEDRAEALANTLFAGMKVQGQYLDQYVDYDFCNPACALGATINDIT4GRLKQVAGCANNQGONN VHPGALGVERSIVYAPDFUN4AGGLILGNNVYHLGNYKNALEVLELFYNNADSLNISTHAANAFIKQIKGGQLN NFKIR |
| *Arenimonas sp. SCN 70-307*   | 1.8                                    | MIFETISTSNHEVYCHNKDAGLKAI6HTNLGPGTAGTSV5WYASEEALNKDVLRLS6RMGTYKAAY GNLNLGQAKVIGADAKTKTEALLRLKRFGRFQLNLYTAE5DNMTDREYRMIEMTK HVA5LPGMSGGSSPSTVAGTYMGKAAKAAGFSGSLARKRAGQVQGQHYLVLLGKNFKEAKYKTEINE YLVDYEDRAEALANTLFAGMKVQGQYLDQYVDYDFCNPACALGATINDIT4GRLKQVAGCANNQGONN VHPGALGVERSIVYAPDFUN4AGGLILGNNVYHLGNYKNALEVLELFYNNADSLNISTHAANAFIKQIKGGQLN NFKIR |
| *Peptococcaceae bacterium CEB3* | 1.9                                    | MTTFEMKYDEYERVGLCQDISNTSLKAVCHD6HTDLGPGTAGTMWYASEEALNMTLRLS6RMGTYKAAY GNLNLGQAKVIGADAKTKTEALLRLKRFGRFQLNLYTAE5DNMTDREYRMIEMTK HVA5LPGMSGGSSPSTVAGTYMGKAAKAAGFSGSLARKRAGQVQGQHYLVLLGKNFKEAKYKTEINE YLVDYEDRAEALANTLFAGMKVQGQYLDQYVDYDFCNPACALGATINDIT4GRLKQVAGCANNQGONN VHPGALGVERSIVYAPDFUN4AGGLILGNNVYHLGNYKNALEVLELFYNNADSLNISTHAANAFIKQIKGGQLN NFKIR |
| *Candidatus kapabacteria sp.* | 1.1                                    | MOIFDTLSOM5MHEQVVFCLSCDKTTLGRIAI6HIDDLGPGTAGTMWYASEEALNMTLRLS6RMGTYKAAY GNLNLGQAKVIGADAKTKTEALLRLKRFGRFQLNLYTAE5DNMTDREYRMIEMTK HVA5LPGMSGGSSPSTVAGTYMGKAAKAAGFSGSLARKRAGQVQGQHYLVLLGKNFKEAKYKTEINE YLVDYEDRAEALANTLFAGMKVQGQYLDQYVDYDFCNPACALGATINDIT4GRLKQVAGCANNQGONN VHPGALGVERSIVYAPDFUN4AGGLILGNNVYHLGNYKNALEVLELFYNNADSLNISTHAANAFIKQIKGGQLN NFKIR |

Table S3. KivD enzyme performance

| KivD Source                  | Activity relative to assay background | Protein sequence                                                                 |
|-------------------------------|----------------------------------------|---------------------------------------------------------------------------------|
|                                | 1.0                                    | MFWKLMIFQGFQ2FFQYALLGSKFGRFQLNLYTAE5DNMTDREYRMIEMTK HVA5LPGMSGGSSPSTVAGTYMGKAAKAAGFSGSLARKRAGQVQGQHYLVLLGKNFKEAKYKTEINE YLVDYEDRAEALANTLFAGMKVQGQYLDQYVDYDFCNPACALGATINDIT4GRLKQVAGCANNQGONN VHPGALGVERSIVYAPDFUN4AGGLILGNNVYHLGNYKNALEVLELFYNNADSLNISTHAANAFIKQIKGGQLN NFKIR |
|                                | 1.1                                    | MFWKLMIFQGFQ2FFQYALLGSKFGRFQLNLYTAE5DNMTDREYRMIEMTK HVA5LPGMSGGSSPSTVAGTYMGKAAKAAGFSGSLARKRAGQVQGQHYLVLLGKNFKEAKYKTEINE YLVDYEDRAEALANTLFAGMKVQGQYLDQYVDYDFCNPACALGATINDIT4GRLKQVAGCANNQGONN VHPGALGVERSIVYAPDFUN4AGGLILGNNVYHLGNYKNALEVLELFYNNADSLNISTHAANAFIKQIKGGQLN NFKIR |
### Lactococcus lactis (prototype)

| MYTVDGYLDRLHELIEGIEGFPGVYPDNLQLDLSQHOKMKVWWWANLNEASYMADGVRTKAAAFL | 1 |
| TTTFGVGGELSAVLGLAYAENLVPEVEIQGPTKVTQONGKFVNHITLADGPKHMHHMTVEPTTLL | |
| AENATVEIDRVLASSLKERKPKTVNYLPLVDDIAAKAEKSPFLUKKSENSTSSQDEILKWSQELNKA| |
| NKAPKPVW | TGHISGFLQESGKQVTPKTTKLTPQNILFQKSSQDAEFLQSLFLQYIOITNL | |
| MYTVGDYLLDRLHELGIEEIFGVPGDYNLQFLDQIISHKDMKWVGNANELNASYMADGYARTKKAAAFL | |
| TTFGVGELSAVNGLAGSYAENLPVVEIVGSPTSKVQNEGKFVHHTLADGDFKHFMKMHEPVTAARTLL | |
| AENATVEIDRVLSALLKERKPKPVYINLPVDIAAKAEKSPFLUKKSENSTSSQDEILKWSQELNKA| |
| NKAPKPVW | TGHISGFLQESGKQVTPKTTKLTPQNILFQKSSQDAEFLQSLFLQYIOITNL | |

### Candida auris

| MSEITLGRYLFERNNLNOVLQOTIPIGRLPGDNLSLDDIIYEVDMGMRWQANLINGNLAAAYAAGYSRVKGLAC | 9.6 |
| LTFTVGGELSAVNGLAGSYAENLPVVEIVGSPTSKVQNEGKFVHHTLADGDFKHFMKMHEPVTAARTLL | |
| AENATVEIDRVLSALLKERKPKPVYINLPVDIAAKAEKSPFLUKKSENSTSSQDEILKWSQELNKA| |
| NKAPKPVW | TGHISGFLQESGKQVTPKTTKLTPQNILFQKSSQDAEFLQSLFLQYIOITNL | |

### Bacillus sp. FJAT-18017

| MTSMDSQSOOPMKGQKTVGFEDCLOKQEGITEIFGVGDYNFNTLDDLAEOYQNYQRFNGRNELNAGY | 9.0 |
| ADGYARIKQIISSININFGTEYTDFDQNYQPSKQAPTKQPPNQELINVQKYSQVCHDLSHAWHGDWPTP| |
| KLPLVQDHGHEGAPAATPHELRAAVLDAEDAEMCALQADA | |
| VILLAFLADLADQGRTVLRALAWKIQDVPHMILTLLMGKQILSEQOQPQVTVGTVAYQASSDSTRGFAI| |
| EGTVQVRQGDNYTQPPNQELINVQKYSQVCHDLSHAWHGDWPTP | |

### Erwinia iniecta

| MSTTTVGDYLLRNEIGLFVPVQDNLQLDLSQHOKMKVWWWANLNEASYMADGVRTKAAAFL | 8.7 |
| LTTTFVGGELSAVLGLAYAENLVPEVEIQGPTKVTQONGKFVNHITLADGPKHMHHMTVEPTTLL | |
| AENATVEIDRVLASSLKERKPKTVNYLPLVDDIAAKAEKSPFLUKKSENSTSSQDEILKWSQELNKA| |
| NKAPKPVW | TGHISGFLQESGKQVTPKTTKLTPQNILFQKSSQDAEFLQSLFLQYIOITNL | |

---

**Table S4. Adh enzyme performance**

| Adh Source | Activity relative to assay background | Protein sequence |
|------------|---------------------------------------|------------------|
| **Equus caballus** (positive control) | 1.0 | MSIPETQKAIFYESNGNKLHDKIIPVPKPNELLNIKVGCHTDLHAWGDPWPTKLPLVQHGHEGAPGTVFQGDKV | |
| | | QGIVVQMGENVKQINDGQYASKRNLSNGCMAEYCENEGSNCPHDGSDGQYCTADAVAIAHHPGQTLAEL | |
| | | VAILическаяGДЛСНКMAЕYCENEGSNCPHDGSDGQYCTADAVAIAHHPGQTLAEL | |

| **Tortospora caseinolytica** NRRL Y-17796 | 12 | MOATALFYQKQHENLVEIPPIPKGARQGEVYLEKAAGHCHDSDLVLGDPGQPGFFMHEGVGTIHEDQ | |
| | | QGIVVQMGENVKQINDGQYASKRNLSNGCMAEYCENEGSNCPHDGSDGQYCTADAVAIAHHPGQTLAEL | |
| | | VAILическаяGДЛСНКMAЕYCENEGSNCPHDGSDGQYCTADAVAIAHHPGQTLAEL | |

| **Rhizobiales bacterium NLR2** | 12 | MRSMDQMFQDEGAPLKFAYSEDPTQPOKVEVRIAEQGVCHSIDLHHEFGDOMGGKNAVDTRERELFPT | |
| | | LGHEIGVEGAVAGPIGPTKVTQONGKFVNHITLADGPKHMHHMTVEPTTLL | |
| | | AENATVEIDRVLASSLKERKPKTVNYLPLVDDIAAKAEKSPFLUKKSENSTSSQDEILKWSQELNKA| |
| | | NKAPKPVW | TGHISGFLQESGKQVTPKTTKLTPQNILFQKSSQDAEFLQSLFLQYIOITNL | |

**SK**

---

**Table S4. Adh enzyme performance**

| Adh Source | Activity relative to assay background | Protein sequence |
|------------|---------------------------------------|------------------|
| **Equus caballus** (positive control) | 1.0 | MSIPETQKAIFYESNGNKLHDKIIPVPKPNELLNIKVGCHTDLHAWGDPWPTKLPLVQHGHEGAPGTVFQGDKV | |
| | | QGIVVQMGENVKQINDGQYASKRNLSNGCMAEYCENEGSNCPHDGSDGQYCTADAVAIAHHPGQTLAEL | |
| | | VAILическаяGДЛСНКMAЕYCENEGSNCPHDGSDGQYCTADAVAIAHHPGQTLAEL | |

| **Tortospora caseinolytica** NRRL Y-17796 | 12 | MOATALFYQKQHENLVEIPPIPKGARQGEVYLEKAAGHCHDSDLVLGDPGQPGFFMHEGVGTIHEDQ | |
| | | QGIVVQMGENVKQINDGQYASKRNLSNGCMAEYCENEGSNCPHDGSDGQYCTADAVAIAHHPGQTLAEL | |
| | | VAILическаяGДЛСНКMAЕYCENEGSNCPHDGSDGQYCTADAVAIAHHPGQTLAEL | |

| **Rhizobiales bacterium NLR2** | 12 | MRSMDQMFQDEGAPLKFAYSEDPTQPOKVEVRIAEQGVCHSIDLHHEFGDOMGGKNAVDTRERELFPT | |
| | | LGHEIGVEGAVAGPIGPTKVTQONGKFVNHITLADGPKHMHHMTVEPTTLL | |
| | | AENATVEIDRVLASSLKERKPKTVNYLPLVDDIAAKAEKSPFLUKKSENSTSSQDEILKWSQELNKA| |
| | | NKAPKPVW | TGHISGFLQESGKQVTPKTTKLTPQNILFQKSSQDAEFLQSLFLQYIOITNL | |
Table S5. Key DNA sequence of operons used in this study

| Operon | DNA sequence |
|--------|--------------|
| **leuDH-kivD-adh-brnQ** (in SYN1980 and SYN6034) | |
Figures

A

Branched chain amino acids and human diseases. A) Branched chain amino acids (BCAAs) are essential amino acids which humans must obtain from protein food. They benefit human health but also are believed to relate to various diseases and disorders. B) Abnormal degradation due to defective enzymes in humans will result in severe disorders such as maple syrup urine disease.
disease (MSUD), propionic acidemia (PA), methylmalonic acidemia (MMA), isovaleryl acidemia (IVA), or 3-methylcrotonyl-CoA carboxylase deficiency (3-MCC).

**Figure 2**

BCAA degradation pathway design, strain construction and in vitro activity. A) Leucine consumption pathway designed to engineer into EcN in this study. B) The scheme of prototype strain SYN1980. C) The scheme of prototype strain SYN6034. D) In vitro leucine consumption of engineered prototype strains (n = 2 for each timepoint and the error bar indicates the range of duplicates, solid lines indicate the linear regression fit of means for each strain).
Figure 3

High throughput enzyme and operon screening results. A) The top 110 LeuDH enzymes from the primary screen were re-screened to validate enzyme activity (n = 4). Activities are reported as fold-improvement over the B. cereus LeuDH activity (green dot and green dashed line). B) The top 55 KivD enzymes from the primary screen were re-screened for activity (n = 4). Activities are reported as fold-improvement over the L. lactis KivD, which was equivalent to the non-zero assay background (green dashed line). C) Top 55 Adh enzymes from the primary screen were re-screened for activity (n = 4). Since the strain expressing S. cerevisiae ADH2 had no measurable activity in this assay, activities are reported relative to E. caballus Adh (green dot, green dashed line). D) Pathway operons with optimized enzymes were screened for leucine consumption. Strains were assayed in biological replicates (n = 2 or 3, depending on the number of successful transformants). Data points are shown as dots, and the average for each strain is shown as a horizontal blue line. Control and reference strains are indicated with colored labels.
Confirmation of leucine consumption activity of the top strains after scaling up in fermenter. Original host strain was used as the chassis to test the activity (SYN1980, SYN5721, SYN5722, SYN5729, solid symbols with solid lines indicating the linear regression fit of means). The same four plasmids were also transformed into wild type EcN strain resulting in strains SYN6034, SYN5941, SYN5942, SYN5943). The corresponding in vitro activity was measured (empty symbols with dotted line indicating the linear regression fit of means).

**Figure 4**

**Figure 5**
In vivo biomarker validation and strain activity in mice. A) Proposed pathway of in vivo isopentyl glucuronide (IPG) formation. B) IPG urinary recovery in response to oral administration of isopentanol in mice (n = 5 for each group). Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test (****p < 0.0001, ***p < 0.0007 versus vehicle). C) IPG urinary recovery in response to orally administered leucine consuming strain SYN5941 in mice (n = 5 for each group, bacterial dosed at 0 h, 1 h and 2 h and totaled at 5.62 e10 cells). All vehicle & SYN094 samples are below limit of quantification = 0.00003 μmol. Statistical analysis was performed using two-way ANOVA analysis followed by Tukey’s multiple comparison test (****p < 0.0001 versus vehicle).
Figure 6

Efficacy of SYN1980 or SYN5941 in healthy nonhuman primates. A) Effect of SYN1980 and SYN5941 on plasma leucine levels following oral administration of leucine consuming strains. Statistical analysis was performed using two-way ANOVA analysis followed by Tukey's multiple comparison test (* p < 0.05 versus vehicle). B) Quantification of area under the curves (AUC) from plot A in this figure. Statistical analysis was performed using ordinary one-way ANOVA analysis (**p < 0.0051 versus vehicle) followed
by Tukey's multiple comparison test. C) Urinary IPG recovery following oral administration of leucine consuming strains. Statistical analysis was performed using one-way ANOVA analysis followed by Tukey's multiple comparison test (**p < 0.005 versus vehicle).